APLS - CIK 0001492422
Apellis Pharmaceuticals, Inc. trades as APLS and has a market capitalization of $5.25 B, making it the #1353 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.00B, up 28.5% from the prior year and net income of $22.39M. This page tracks Apellis Pharmaceuticals, Inc. through 1,217 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Apellis Pharmaceuticals, Inc.'s revenue grew from $250.65M to $1.00B, a compound annual growth rate of 32.0%. Net profit margin expanded from -137.6% to 2.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| 15-12G | - | 2026-05-26 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Delisting notice | 25-NSE | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology | Apellis Pharmaceuticals, Inc.
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors | Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Apellis Pharmaceuticals, Inc.
Please ensure Javascript is enabled for purposes of website accessibility
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference | Apellis Pharmaceuticals, Inc.
The largest companies sharing Apellis Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Apellis Pharmaceuticals, Inc. (APLS) has a market capitalization of $5.25 B as of 2026-06-10, ranking #1353 among US-listed companies.
Apellis Pharmaceuticals, Inc. reported revenue of $1.00B for fiscal year 2025, an increase of 28.5% year over year.
Yes. Apellis Pharmaceuticals, Inc. reported net income of $22.39M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.